[68Ga]Ga-DOTA-TATE + 68Ge/68Ga Generator

Phase 3Completed

3 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neuroendocrine Neoplasms

Conditions

Neuroendocrine Neoplasms

Trial Timeline

Mar 21, 2024 → Dec 27, 2024

NCT ID

NCT06240741

About [68Ga]Ga-DOTA-TATE + 68Ge/68Ga Generator

[68Ga]Ga-DOTA-TATE + 68Ge/68Ga Generator is a phase 3 stage product being developed by Novartis for Neuroendocrine Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT06240741. Target conditions include Neuroendocrine Neoplasms.

What happened to similar drugs?

6 of 15 similar drugs in Neuroendocrine Neoplasms were approved

Approved (6) Terminated (2) Active (8)

✅Everolimus (RAD001)NovartisApproved

✅Pasireotide + DiazoxideNovartisApproved

✅everolimusNovartisApproved

✅sunitinibPfizerApproved

✅lanreotide acetateIpsenApproved

✅lanreotide (Autogel formulation)IpsenApproved

🔄Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.Jiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06240741	Phase 3	Completed	Mar 21, 2024	Dec 27, 2024	Neuroendocrine Neoplasms

Competing Products

20 competing products in Neuroendocrine Neoplasms

See all competitors

Product	Company	Stage	Hype Score
[203Pb]VMT-α-NET + [212Pb]VMT-α-NET	Perspective Therapeutics	Phase 1/2	33
[203Pb]VMT-α-NET	Perspective Therapeutics	Phase 1	27
[212Pb] VMT-α-NET	Perspective Therapeutics	Phase 1	27
Lenvatinib	Eisai	Phase 2	35
Abemaciclib	Eli Lilly	Phase 2	39
Lutetium (177Lu) Oxodotreotide Injection；long-acting Octreotide + long-acting Octreotide.	Jiangsu Hengrui Medicine	Phase 3	47
Famitinib	Jiangsu Hengrui Medicine	Phase 2	27
68Ga-DOTATOC	Jiangsu Hengrui Medicine	Phase 3	47
Olaparib	AstraZeneca	Phase 2	27
Avelumab	Merck	Phase 1/2	32
Pembrolizumab	Merck	Phase 2	27
Lenvatinib + Pembrolizumab + Hyperpolarized 13C-Pyruvate	Merck	Phase 2	42
Pembrolizumab	Merck	Phase 2	35
Pembrolizumab Injection	Merck	Phase 2	27
Carboplatin + Cisplatin + Docetaxel + Etoposide + Pembrolizumab	Merck	Phase 1	33
Avelumab	Merck	Phase 2	35
Pembrolizumab + Lenvatinib	Merck	Phase 2	35
Avelumab	Merck	Phase 2	35
Pembrolizumab + Irinotecan + Paclitaxel	Merck	Phase 2	35
MK-0646	Merck	Phase 2	35